Rising Use of GLP-1 Medications Sparks Controversy
The usage of GLP-1 medications is increasing significantly across the globe. A recent Gallup poll found that 11% of American adults now report using these medications, a rise from just 3% in 2024.
Initially prescribed for Type 2 diabetes, GLP-1s are now also used for obesity and can help lower blood pressure and reduce heart disease risks. Many healthcare professionals and users consider these drugs to be remarkably beneficial due to their various health improvements.
However, former President Donald Trump has often belittled the medications, using terms like “fat shots” and “fat drugs.” This rhetoric, which he has maintained for months while sharing anecdotes about friends using these medications, appears dismissive and insulting to many.
Such language is not only flippant but can also perpetuate stigma against those who depend on these medications. To gauge public opinion on Trump’s terminology, views from GLP-1 users and medical experts were sought.
“My focus is less on his words and more on access to these crucial medications.”
“GLP-1s are fantastic medications. They’re not just for weight loss but are effective for diabetes, heart conditions, and even sleep apnea,” remarked one healthcare professional. “I often don’t pay much attention to how Trump speaks. We know he’s not the most articulate and uses stigmatizing language often. What really concerns me is the lack of Medicaid coverage for these life-saving drugs. I wish he’d focus on pushing for legislation to get these covered instead of labeling them.”
“Referring to these drugs as ‘fat shots’ is irresponsible and diminishes their significance.”
Another expert emphasized that GLP-1s have numerous applications, highlighting their original approval for treating Type 2 diabetes but also noting their benefits for obesity and other conditions. “Labeling them as ‘fat shots’ reduces the validity of their medical purpose, making them seem like vanity drugs rather than something that treats serious health issues,” she said.
“It’s not about being ‘fat.’”
A user shared, “I’ve been on weekly shots for nearly two years to manage my A1C levels. Despite no weight loss, my A1C has significantly improved. It’s not solely about weight.”
“His comments increase stigma and shame.”
Commenting on the implications of Trump’s words, another observer noted that such statements reflect a long history of insensitivity, akin to his past mocking of individuals with disabilities. While recognizing that initiatives to lower drug prices are valuable, they added that Trump’s framing lacks empathy and exacerbates stigma surrounding a population that already faces considerable discrimination.
“His language reinforces negative stereotypes about obesity.”
A healthcare expert pointed out that Trump’s casual usage of derogatory terms reflects a societal tendency towards fatphobia. This kind of rhetoric dismisses the complex reality of obesity, instead treating it as a simple moral failing rather than acknowledging the broader societal issues at play.
“Obesity is a multifaceted health issue. I ignore his remarks.”
One individual expressed frustration with the stigma associated with GLP-1s and stated, “These medications saved my life. I don’t really care what anyone thinks about them.” This sentiment echoed amongst others who stressed that people should focus on health rather than derogatory labels.
Another user shared their struggle with obesity and how GLP-1s helped them improve their quality of life, emphasizing that calling them “easy solutions” doesn’t capture the reality of the profound effort and lifestyle changes required.
In conclusion, while the conversation around GLP-1 medications is increasingly visible, the rhetoric surrounding them—especially from figures like Trump—can have meaningful implications. The user experiences and opinions highlight a desire for empathy and understanding in addressing such essential health treatments.
